News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

29,773 signal articles · 63 in last 24h · 148,348 total before filter · latest 2h ago

63last 24h

973last 7d

109● bullish (7d)

123● bearish (7d)

212publishers

All Macro369 Earnings115 M&A98 Regulatory8 Product11 Analyst10

✕ clear all filtersticker: GILDsentiment: bearishSentiment:bullish neutral bearish show all (incl. clickbait)

Barrons.com134d agobearish

Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut?

Gilead Sciences beat analysts’ earnings and revenue expectations in its latest quarter. Gilead logged adjusted earnings of $2.03 a share, ahead of the $1.91 consensus among analysts polled by FactSet. Gilead’s top-line growth rested heavily on Biktarvy, its blockbuster HIV treatment, which accounted for nearly half of total revenue as sales rose 8% to $3.4 billion.

GILD

Reuters134d agobearish

Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions

By Deena Beasley LOS ANGELES, May 7 (Reuters) - Gilead Sciences on Thursday posted a higher-than-expected first-quarter profit and raised its outlook for 2026 sales, but said it now expects a loss for

GILD